mM or 5 mM) for 2 h (30 min., 37°C) and aliquots collected for analysis. Monomer $A\beta_{1-40}$ is indicated.

Sequence Listing:

At the end of the specification, please insert the Sequence Listing that is appended hereto.

In the Claims:

Please substitute the following claim 1 for the pending claim 1:

C7

1. (Twice amended) A method of treating amyloidosis in a subject, said method comprising administering to said subject an effective amount of (a) bathocuproine or a hydrophobic derivative thereof; and (b) one or more pharmaceutically acceptable carriers or diluents; for a time and under conditions to bring about said treatment; and

wherein said chelator reduces, inhibits or otherwise interferes with amyloid beta peptide (Aβ)-mediated production of radical oxygen species.

Please substitute the following claim 2 for the pending claim 2:

C8

2. (Once amended) The method of claim 1 further comprising administering to the subject an effective amount of indomethacin, or a pharmaceutically acceptable salt thereof.

Please substitute the following claim 37 for the pending claim 37:

C9

37. (Twice amended) A pharmaceutical composition for treatment of conditions caused by amyloidosis, amyloid beta peptide (Aβ)-mediated reactive oxygen species (ROS) formation, or both, comprising: (a) bathocuproine or a hydrophobic derivative thereof; and (b) one or more pharmaceutically acceptable carriers or diluents.

Please substitute the following claim 38 for the pending claim 38:

C10

38. (Once amended) The pharmaceutical composition of claim 37 further comprising indomethacin, or a pharmaceutically acceptable salt thereof.

Please substitute the following claim 53 for the pending claim 53:

C11

53. (Once amended) A composition of matter comprising: (a) bathocuproine or a hydrophobic derivative thereof; and (b) indomethacin.